Macroprolactinomas will usually shrink with dopamine agonist therapy, often to within the pituitary fossa; definitive treatment with radiotherapy can then achieve eventual normalization of serum prolactin in the majority of patients. Persistent suprasellar extensions, even when relatively large, can usually be successfully decompressed by the transsphenoidal route. Stalk compression can also give rise to hyperprolactinemia that will normalize with bromocriptine, but tumors causing it will rarely, if ever, show significant shrinkage in response to the drug
The aim of the present study was to investigate the effect of a new galenic injectable form of bromo...
About 3-5% of pituitary tumors occur in pediatric patients, often showing a considerable severity du...
Five patients with PRL-secreting macroadenoma and nine patients with PRL-secreting microadenoma or i...
Macroprolactinomas will usually shrink with dopamine agonist therapy, often to within the pituitary ...
The objectives of the treatment of hyperprolactinaemia are to suppress excessive hormone secretion a...
Objectives Macroprolactinomas are pituitary tumours that can be managed with dopamine agonists (DA),...
Abstract. Prolactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tum...
International audienceIntroduction: Prolactinomas represent the most common pituitary adenomas encou...
Prolactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tumors. Medic...
Copyright © 2013 Atanaska Elenkova et al. is is an open access article distributed under the Creativ...
In women with micro- or small infrasellar or inferiorly extending macroprolactinomas, treatment with...
PURPOSE: To study the changes in macroprolactinomas during long-term bromocriptine therapy by means ...
About 3-5% of pituitary tumors occur in pediatric patients, often showing a considerable severity du...
Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical attention an...
Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the...
The aim of the present study was to investigate the effect of a new galenic injectable form of bromo...
About 3-5% of pituitary tumors occur in pediatric patients, often showing a considerable severity du...
Five patients with PRL-secreting macroadenoma and nine patients with PRL-secreting microadenoma or i...
Macroprolactinomas will usually shrink with dopamine agonist therapy, often to within the pituitary ...
The objectives of the treatment of hyperprolactinaemia are to suppress excessive hormone secretion a...
Objectives Macroprolactinomas are pituitary tumours that can be managed with dopamine agonists (DA),...
Abstract. Prolactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tum...
International audienceIntroduction: Prolactinomas represent the most common pituitary adenomas encou...
Prolactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tumors. Medic...
Copyright © 2013 Atanaska Elenkova et al. is is an open access article distributed under the Creativ...
In women with micro- or small infrasellar or inferiorly extending macroprolactinomas, treatment with...
PURPOSE: To study the changes in macroprolactinomas during long-term bromocriptine therapy by means ...
About 3-5% of pituitary tumors occur in pediatric patients, often showing a considerable severity du...
Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical attention an...
Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the...
The aim of the present study was to investigate the effect of a new galenic injectable form of bromo...
About 3-5% of pituitary tumors occur in pediatric patients, often showing a considerable severity du...
Five patients with PRL-secreting macroadenoma and nine patients with PRL-secreting microadenoma or i...